FGF1
Fibroblast growth factor 1
As of the edition of 20 October 2026, FGF1 (fibroblast growth factor 1, UniProt P05230) has 5 drugs tested at it and 9 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P05230
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 96
- Disease areas
- Cancer; Digestive system; Urinary and reproductive; Hormones; Lungs and airways; Nutrition and metabolism; Pregnancy and women's health; Skin and connective tissue
- Registered trials of its drugs
- 58
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 4 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Suramin | Marketed | Phase 3 | none listed |
| Aldafermin | Stopped | Phase 3 | none listed |
| Pegbelfermin | Stopped | Phase 2 | none listed |
| Muparfostat | Stopped | Phase 3 | none listed |
| Fazpilodemab | Stopped | Phase 2 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Undetermined | 7 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Cellxpert Biotechnology | Route A |
| Progen Pharmaceuticals | Route A |
The other 7 companies at FGF1
In the product9 companies in all; 7 are not named here, and no score is.
See the 9 companies at FGF1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.